Last week, Hutchison MediPharma, a division of Chi-Med, dosed the first patient in a China Phase III clinical trial of fruquintinib (HMPL-013), a treatment for solid tumor cancers. The trial will enroll more than 400 patients with advanced colorectal cancer who have already failed two previous antineoplastic therapies. In 2013, Hutchison MediPharma out-licensed China rights for fruquintinib to Lilly in a deal worth up to $86.5 million in upfront and milestone payments.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
